{"id":"W4403709325","doi":"10.1182/blood.2024025454","title":"Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Spinal Cord Injury BC; Jewish General Hospital; BC Cancer Agency","funders":"Daiichi Sankyo Europe; Janssen Research and Development; Royal Adelaide Hospital; BeiGene; Incyte; F. Hoffmann-La Roche; Pharmacyclics; Genentech; MEI Pharma; Teva Pharmaceutical Industries; Kite Pharma; Gilead Sciences; TG Therapeutics; Amgen; Pfizer; MorphoSys; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Follicular lymphoma; Confidence interval; Refractory (planetary science); Gastroenterology; Adverse effect; Cytokine release syndrome; Surgery; Lymphoma; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002011747,0.0003181891,0.001028391,0.0004590846,0.0005872782,0.0007650636,0.000329891,0.0006892501,0.000975134],"category_scores_gemma":[0.001979525,0.0001715531,0.0009627045,0.0004226253,0.0002163179,0.0005992693,0.0003388008,0.001062357,0.0004089134],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007352865,"about_ca_system_score_gemma":0.0002697897,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001786608,"about_ca_topic_score_gemma":0.001830605,"domain_scores_codex":[0.9993895,0.0001618297,0.00006796368,0.0001187764,0.0001165391,0.0001454504],"domain_scores_gemma":[0.9983327,0.000352456,0.000611105,0.000123204,0.0002414543,0.000339044],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0353028,0.002097023,0.8465791,0.0002058958,0.002006463,0.001917897,0.0004637225,0.001527166,0.01332446,0.0000893298,0.002158506,0.09432764],"study_design_scores_gemma":[0.0008942421,0.01023739,0.9801723,0.00004315203,0.001421238,0.001296147,0.0001040685,0.001245259,0.001894636,0.00006583163,0.002594316,0.00003134809],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9948013,0.00312645,0.0002952923,0.0001090884,0.00002070146,0.00004900869,0.0006898436,0.00002446342,0.0008838793],"genre_scores_gemma":[0.9982359,0.0002650679,0.00006381937,0.0001049527,0.00002102383,0.00002108959,0.0009929823,0.000003153681,0.0002918696],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002011747,"threshold_uncertainty_score":0.01063925,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01866792604861877,"score_gpt":0.2919711297431507,"score_spread":0.2733032036945319,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}